Skip to content
10-K

Annual Report

Arcus Biosciences, Inc. RCUS

0001724521-26-000009

← back to feed
Filed
Feb 25, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 19, 2026 125.35M sh
Shares Diluted FY 2025 · Dec 31, 2025 107.4M sh
Shares Diluted FY 2025 · Dec 31, 2024 90.1M sh
Shares Diluted FY 2025 · Dec 31, 2023 74M sh
Capex FY 2025 · Dec 31, 2025 $2M
Capex FY 2025 · Dec 31, 2024 $6M
Capex FY 2025 · Dec 31, 2023 $24M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$482M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$170M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$306M
Long Term Debt FY 2025 · Dec 31, 2025 $99M
Long Term Debt FY 2025 · Dec 31, 2024 $48M
Cash And Equivalents FY 2025 · Dec 31, 2025 $222M
Cash And Equivalents FY 2025 · Dec 31, 2024 $150M
Stockholders Equity FY 2025 · Dec 31, 2025 $631M
Stockholders Equity FY 2025 · Dec 31, 2024 $485M
Stockholders Equity FY 2025 · Dec 31, 2023 $462M
Stockholders Equity FY 2025 · Dec 31, 2022 $657M
Current Liabilities FY 2025 · Dec 31, 2025 $231M
Current Liabilities FY 2025 · Dec 31, 2024 $226M
Current Assets FY 2025 · Dec 31, 2025 $1.01B
Current Assets FY 2025 · Dec 31, 2024 $1.02B
Total Assets FY 2025 · Dec 31, 2025 $1.14B
Total Assets FY 2025 · Dec 31, 2024 $1.15B
Eps Diluted FY 2025 · Dec 31, 2025 −$3.29
Eps Diluted FY 2025 · Dec 31, 2024 −$3.14
Eps Diluted FY 2025 · Dec 31, 2023 −$4.15
Eps Basic FY 2025 · Dec 31, 2025 −$3.29
Eps Basic FY 2025 · Dec 31, 2024 −$3.14
Eps Basic FY 2025 · Dec 31, 2023 −$4.15
Sga Expense FY 2025 · Dec 31, 2025 $110M
Sga Expense FY 2025 · Dec 31, 2024 $120M
Sga Expense FY 2025 · Dec 31, 2023 $117M
Rd Expense FY 2025 · Dec 31, 2025 $523M
Rd Expense FY 2025 · Dec 31, 2024 $448M
Rd Expense FY 2025 · Dec 31, 2023 $340M
Net Income FY 2025 · Dec 31, 2025 −$353M
Net Income FY 2025 · Dec 31, 2024 −$283M
Net Income FY 2025 · Dec 31, 2023 −$307M
Operating Income FY 2025 · Dec 31, 2025 −$386M
Operating Income FY 2025 · Dec 31, 2024 −$330M
Operating Income FY 2025 · Dec 31, 2023 −$340M
Revenue FY 2025 · Dec 31, 2025 $33M
Revenue FY 2025 · Dec 31, 2024 $51M
Revenue restated FY 2025 · Dec 31, 2023 $37M